Amerigen Launches Generic Bexarotene Capsules

Thursday, June 7, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

LYNDHURST, N.J., June 7, 2018 /PRNewswire/ -- Amerigen Pharmaceuticals Limited ("Amerigen") today announced the commercial

launch of its generic bexarotene 75mg capsules following the recent approval of the Company's corresponding Abbreviated New Drug Application ("ANDA") by the U.S. Food and Drug Administration. Amerigen's bexarotene product is a generic equivalent to Valeant
Pharmaceuticals' TargretinŪ Capsules. Amerigen's generic bexarotene capsules are marketed by Amerigen's U.S. affiliate, Amerigen Pharmaceuticals, Inc.

About AmerigenAmerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the U.S. and China. The group is controlled by Amerigen Pharmaceuticals Limited. The U.S. regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province. 

The group has products on the market currently in both the U.S. and China plus an active portfolio of products under development, filed, or intended for filing, as ANDA's with the U.S. FDA and the Chinese CFDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the U.S. FDA.

AMERIGEN: +1 (732) 993-9821info@amerigenpharma.com  www.amerigenpharma.com

Cision View original content:http://www.prnewswire.com/news-releases/amerigen-launches-generic-bexarotene-capsules-300661704.html

SOURCE Amerigen Pharmaceuticals



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store